‘Skinny Labeling’ Case To Be Reheard
The term refers to an effort by a generic company to seek regulatory approval to market its medicine for a specific use, but not other patented uses. An October ruling in a patent case prompted hand-wringing that many Americans might be deprived of access to generic drugs, Stat reported. But Tuesday, the ruling was vacated, with new arguments scheduled for Feb. 23.